...the only investor in a series A round. MICA is an activating ligand for the NKG2D... ...Approach” ). Targets MICA - MHC class I polypeptide-related sequence A NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1
Lauren... ...Killer cell lectin-like receptor subfamily K member 1
Lauren Martz, Senior Editor
Cullinan Oncology LLC
PDI Therapeutics Inc.
Avalon Ventures
MHC class I polypeptide-related sequence A (MICA)
Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)...
Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
...report additional data from the trial in 1H20. CYAD-101 is an allogeneic CAR T targeting NKG2D... ...Targets: IL2RB (CD122) - Interleukin-2 receptor β chain; IL-15 - Interleukin-15; NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1...
With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
...from causing graft-versus host disease (GvHD). In the other, it uses shRNA to prevent its NKG2D-based... ...a next-generation version of its NKG2D-based CAR that used shRNA knockdown to reduce expression of NKG2D... ...chemokine receptor 5 CD3ζ (CD247) miR-30 - MicroRNA-30 miR-196a - MicroRNA-196a NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1...
Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
